Better Buy: Amgen vs. Mirati Therapeutics

Investors looking for biotech stocks to buy will notice lots of buzz around Amgen (NASDAQ: AMGN) and Mirati Therapeutics (NASDAQ: MRTX) lately. Both companies are developing similar new cancer treatments that could go on to generate billions in annual sales, and there are plenty of arguments over which company has the best one.

Which one of these stocks is a better fit for your portfolio? Let's have a look at the case for each to weigh their chances to provide outsize returns.  

Image source: Getty Images.

Continue reading

Source Fool.com